An Introduction to Multiple Myeloma
Despite numerous advances in the last decade, multiple myeloma remains an incurable disease, characterised by relapses that ultimately result in uncontrolled disease and death. However, novel agents, such as proteasome inhibitors, immunomodulatory drugs and CD38-directed monoclonal antibodies, have substantially improved survival and tolerability. These emerging agents include immune checkpoint inhibitors and chimeric antigen receptor-engineered T-cell therapies, although eventual relapse remains an issue.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Our supporting partners do not constitute an endorsement of the content on this page.
Multiple Myeloma Content
The evolving treatment landscape in relapsed/refractory multiple myeloma
Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.
Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
touchREVIEWS in Oncology & Haematology. 2023;19(1):46–51 DOI: https://doi.org/10.17925/OHR.2023.19.1.46
Multiple myeloma (MM) is the second most common haematological malignancy, with upwards of 35,000 diagnoses in the USA each year.1,2 It remains a leading cause of blood cancer–related mortality worldwide, and although therapeutic advances have allowed for significant improvements in the median overall survival,3,4 the majority of patients still experience cycles of relapse that are eventually fatal.5 While patients with MM are living longer, a subgroup with high-risk disease at diagnosis still does poorly, with a median […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Shaji Kumar, ASH 2022: Highlights in older, frail transplant ineligible patients with multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]
Shaji Kumar, ASH 2022: Updated efficacy analysis from the phase III MAIA study in newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]
Shaji Kumar, ASH 2022: Key clinical trials in smoldering myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of three key clinical trials presented at ASH 2022 in the field of smoldering myeloma, an area of great interest and opportunity to improve patient overall survival. Abstract 3253: Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety […]
Shaji Kumar, ASH 2022: Highlights in high-risk newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of high-risk newly-diagnosed multiple myeloma, where it is fundamental to risk stratify patients and develop different treatment strategies. Abstract 752: Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction […]
ATLAS: Risk-adapted Triplet Maintenance with Carfilzomib, Lenalidomide and Dexamethasone – Still Shrugging?
touchREVIEWS in Oncology & Haematology. 2022;18(2):96-7 DOI: https://doi.org/10.17925/OHR.2022.18.2.96
The optimal maintenance approach postautologous stem cell transplantation (ASCT) for patients with multiple myeloma is still an area of ongoing research. Lenalidomide has demonstrated clear superiority in clinical trials compared to placebo, and continuous post-transplant lenalidomide until progression is considered standard of care. All patients, however, do not derive equal benefit from single-agent lenalidomide, and […]
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
A multiple myeloma expert and a community oncologist discuss real-world evidence for frail/elderly patients and its application in practice.
- Explain the role and importance of real-world evidence (RWE) in supporting clinical decision making
- Outline the key RWE related to the treatment of elderly and frail patients with multiple myeloma
- Discuss the management of elderly and frail patients with multiple myeloma in clinical practice
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!